Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
FMR LLC reports beneficial ownership of 6,790,364 shares of CLIMB BIO INC common stock, representing 11.9% of the class as of 06/30/2026. The filing (Schedule 13G) states FMR LLC holds sole dispositive power over these shares and identifies Abigail P. Johnson as having dispositive power. The report lists the issuer CUSIP 28658R106 and provides FMR's principal office in Boston.
RA Capital Management and affiliates updated their ownership disclosure in Climb Bio, Inc., reporting a sizable stake and a board change. The reporting group beneficially owns 23,249,186 shares of common stock, representing 33.0% of the company, including shares underlying pre-funded warrants and stock options exercisable within 60 days.
The filing explains that RA Capital advises multiple funds and accounts that hold Climb Bio securities and has delegated voting and investment power over those positions. A "Beneficial Ownership Blocker" in the pre-funded warrants limits exercises so the group cannot exceed 33.0% ownership. The amendment also notes that on June 29, 2026, RA Capital analyst Dr. Breanna Celebi was appointed to Climb Bio’s board of directors as RA Capital’s designee, replacing Dr. Andrew Levin, who resigned the same day. Additionally, on July 2, 2026, Sera Medicines made a pro rata in-kind distribution of 2,479,872 Climb Bio shares to its members, with RA Capital funds receiving portions of those shares.
Climb Bio, Inc. reported a Form 4 showing a grant of stock options tied to 70,284 shares of common stock at an exercise price of $13.36 per share. The options vest in equal monthly installments from June 29, 2026 over three years and expire on June 29, 2036. The options are held by Ms. Celebi for the benefit of several RA Capital funds and an account, and any net cash or stock received upon exercise must be turned over to RA Capital Management, offsetting advisory fees. The reporting persons disclaim beneficial ownership of the option and underlying shares except to the extent of any pecuniary interest.
Climb Bio, Inc. director Breanna Maurine Celebi was granted a stock option covering 70,284 shares of common stock at an exercise price of $13.36 per share. The option vests in equal monthly installments starting on June 29, 2026 and continuing until the third anniversary of that date, contingent on continued service. Under an arrangement with RA Capital Management, L.P., any net cash or stock from exercising this option must be turned over to RA Capital-managed funds and an account to offset advisory fees, and the reporting person therefore disclaims beneficial ownership of the option and its underlying shares.
Climb Bio, Inc. director Breanna Maurine Celebi has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists her as a director of the company but does not report any share transactions or existing holdings at this time.
Climb Bio, Inc. reported that director Andrew Levin resigned from its board, effective June 29, 2026. On the same day, the board elected Breanna O’Reilly, Ph.D., as a new director, with a term running until the 2027 annual meeting and until a successor is in place.
As a non-employee director, Dr. O’Reilly received a stock option to purchase 70,284 shares at an exercise price of $13.36 per share, vesting in equal monthly installments over three years from June 29, 2026. She will also receive a $40,000 annual cash retainer and ongoing annual equity grants under the company’s non-employee director compensation policy, and is covered by an indemnification agreement for certain expenses related to her board service.
Climb Bio, Inc. President and CEO Aoife Brennan exercised restricted stock units and sold shares in a planned transaction. On June 27, 2026, 68,750 RSUs converted into the same number of common shares as part of a four-year vesting grant. On June 29, 2026, Brennan sold 30,902 common shares at a weighted average price of $13.17 per share pursuant to a Rule 10b5-1 trading plan to cover tax withholding obligations tied to the RSU vesting. After these transactions, Brennan directly owned 87,731 common shares, including 1,751 acquired through the employee stock purchase plan, and continued to hold RSUs scheduled to vest annually over four years.
Climb Bio, Inc. entered an Open Market Sale Agreement with Jefferies LLC that allows it to sell shares of common stock with an aggregate offering price of up to $100.0 million through an at-the-market program under its existing Form S-3 shelf registration.
Sales, if made, will occur from time to time on the Nasdaq Global Market or otherwise at prevailing market prices, with Jefferies earning up to 3.0% of the gross sales price per share. Climb Bio also terminated its prior Equity Distribution Agreement with Oppenheimer, which had provided for up to $22.35 million of potential sales but resulted in no shares being sold before termination.
Climb Bio, Inc. entered into a Sales Agreement with Jefferies LLC to sell, from time to time, up to $100,000,000 of its common stock in an at‑the‑market offering on the Nasdaq Global Market under the symbol CLYM. The sales agent commission is up to 3.0% of gross sales. The prospectus supplement states the last reported sale price was $10.91 per share on June 11, 2026, and that there were 47,768,543 shares outstanding as of March 31, 2026. Net proceeds, if any, will be used for general corporate purposes, including working capital, R&D, clinical development, and potential acquisitions.